Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Financial Analyst Ratings and Price Targets for SiteOne Landscape Supply NYSESITE

Elaine Mendonca by Elaine Mendonca
February 15, 2024
in Breaking News
0
Food Retailers Market Capitalization
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

As of February 15, 2024, financial experts have expressed mixed sentiment towards SiteOne Landscape Supply (NYSE:SITE). Analyst ratings for the company have undergone some changes in the past quarter.

There are two bullish ratings in total, with one being received in the last 30 days, which is a decrease from the rating received three months ago. On the other hand, there have been no somewhat bullish ratings during any period.

One indifferent rating has been given in total, with none received in the last 30 days, which is consistent with the rating given two months ago.

In terms of somewhat bearish ratings, there have been two in total, with one being received in the last 30 days, which is consistent with the rating received three months ago.

There have been no bearish ratings during any period.

The 12-month price targets for SiteOne Landscape Supply have also been updated. The average target now stands at $161.4, representing a 14.67% increase from the previous average of $140.75. The high estimate is $204.00, while the low estimate is $121.00.

Several analysts have made recent evaluations and adjustments. Matthew Bouley from Barclays raised the rating from Underweight to an undisclosed rating with a price target of $145.00, up from the previous $121.00. Keith Hughes from Truist Securities also raised the rating, changing it to Buy with a price target of $204.00, up from the previous $170.00. W. Andrew Carter from Stifel announced a Hold rating with a $167.00 price target.

These evaluations and adjustments made by analysts reflect their responses to changes in market conditions and company performance. Consequently, they have made necessary adjustments to their ratings and price targets.

AMXL Stock Shows Slight Gain Despite Bearish Indicators: Is it a Temporary Surge or the Start of an Upward Trend?

On February 15, 2024, AMLX stock made a slight gain despite bearish indicators. The price increased by $0.11 or 0.73% since the market last closed. AMLX opened at $15.32, $0.25 higher than its previous close. Investors should monitor AMLX’s price movements in the coming days to determine if this gain is temporary or the start of a significant upward trend. Thorough research and analysis should be conducted before making any investment decisions.

AMXL Stock Performance on February 15, 2024: Mixed Results and Contrasting Trends in Revenue and Net Income

AMLX stock performances on February 15, 2024, showed mixed results based on the provided information from CNN Money. The company’s total revenue and net income figures indicate contrasting trends, which may have influenced investor sentiment.

Starting with the total revenue, AMLX reported a significant increase of 7700.0% compared to the previous year, reaching $22.23 million. This indicates strong growth in the company’s top line. Additionally, the company’s total revenue also increased by 4.56% since the last quarter.

On the other hand, AMLX’s net income figures paint a different picture. The company reported a net loss of -$198.38 million for the year, showcasing a decrease of 125.6% compared to the previous year. Furthermore, the net income also decreased by 5.35% since the last quarter.

The earnings per share (EPS) figures further emphasize the financial performance of AMLX. The company reported an EPS of -$2.98 for the year, reflecting a decrease of 96.27% compared to the previous year. Additionally, the EPS also decreased by 4.8% since the last quarter.

These contrasting figures in total revenue, net income, and EPS may have influenced the performance of AMLX stock on February 15, 2024. Investors may have been cautiously optimistic about the company’s revenue growth potential, while also concerned about the declining profitability and net income figures.

It is important to note that stock performance is influenced by various factors, including market conditions, investor sentiment, and overall industry trends. Therefore, it is crucial to consider these factors alongside the financial performance metrics when analyzing stock performances.

Investors and analysts should closely monitor AMLX’s future financial reports to assess whether the company can sustain its revenue growth and improve its profitability. Additionally, keeping an eye on market trends and industry developments will provide valuable insights into the stock’s potential performance in the future.

Tags: AMLX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
MA stock news

Rail Visions Shares Experience Dramatic Surge in Stock Price

Revolutionary and Sustainable Introducing the Vision Marine Phantom

Tech-banking-finance

Summit State Banks Reliable Dividend Payouts and Financial Stability

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com